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Introduction: The prevalence and characteristics of pain are not known in COPD patients. The
purposes of this study were to determine if pain is more common in COPD patients than in
healthy people and if it was related to self-reported physical activity, health related quality
of life (HRQoL) and comorbidities.
Methods: Participants returned a mailed survey package that contained: 1) McGill Pain Ques-
tionnaire (MPQ) and Brief Pain Inventory (BPI) to evaluate pain severity and how pain interferes
with activities; 2) Tampa Scale for Kinesiophobia (TSK) to evaluate fear of movement related
to pain; 3) Short Form-36 (SF-36), to measure HRQoL; 4) Community Health Activities Model
Program for Seniors (CHAMPS) to evaluate physical activity; 5) a form to list medications
and comorbidities.
Results: Forty-seven COPD patients and 47 age- and gender-matched healthy people responded.
People with COPD demonstrated more pain (MPQ and BPI, pZ 0.000), a greater pain-related
interference in their lives (BPI, pZ 0.000), a higher pain-related fear of movement, and lower
frequency and energy expenditure of physical activities (CHAMPS, pZ 0.000) than healthy
people (TSK, p < 0.001). Pain severity (MPQ and BPI) was indirectly correlated to the Physical
Component Score of the SF-36. COPDpatients identifiedpain in theneckand trunk 3.1 timesmore
often than healthy people. The number of comorbidities was the most consistent independent
correlate of pain in COPD patients.
Conclusions: COPDpatients demonstratemore painwhich interfereswith activitiesmore so than
healthy people of similar age. Pain is also negatively associated with HRQoL in COPD.
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Pain in COPD 999IntroductionCOPD is a major health burden worldwide and is estimated to
be the third leading cause of death by 2020.1 The recent
guidelines note the multi-systemic effects of COPD including
its impact on peripheral muscle dysfunction, right heart
failure, malnutrition, depression, and decreased exercise
tolerance.2 These guidelines and other statements provide
solid evidence to support the therapeutic benefit of exercise
and maintaining an active lifestyle.1 However, exercise
prescription and lifelong adherence to physical activity for
peoplewithCOPD is limited.Reasons for the lackofadherence
to physical activity programs require further exploration.
Most commonly, lower extremity (LE) fatigue alone or in
combination with dyspnea has been reported to be major
limiting symptoms during exercise tests and is considered to
limit physical activity of COPD patients.3 Recent reports
suggest that pain may be of equal or greater concern. Pain
was a significant contributor to reduced health related
quality of life asdemonstratedby theHealthUtility Indexand
SF-36 evaluations of people with severe emphysema who
underwent lung volume reduction surgery.4 It has also been
reported in COPD patients toward the end of life5,6 in stable
COPD patients who experienced pain,6,7 and as components
of quality of life.8 However, the characteristics of pain such
as fear of movement due to pain, and its relationship with
comorbidities and physical activity has not be examined.
In addition to an increasingly sedentary lifestyle, several
factors related to the manifestations of the disease may
contribute to pain in people with COPD. Firstly, the activation
of cytokines has a major role in the development of inflam-
matory pain.9 It is therefore tenable that the systemic
inflammatory process contributes to the generation of chronic
and neuropathic pain in people with COPD.10 Secondly, the
hyper-expanded and relatively rigid chest wall11 could posi-
tion thoracic articulations in a hyper extended position and
decrease their range of motion. Abnormal joint position and
limited range of motion contribute to pain in several joint
pathologies12 and similarly, may contribute to thoracic pain
experienced by people with COPD. Lastly, inactivity may
aggravate common age-related comorbidities such as osteo-
arthritis,13 low back pain,12 and osteoporosis.14
Reductions across multiple dimensions in health related
quality of life (HRQoL), including depression, anxiety, and
mental health, and activity limitation have been reported in
nonmalignant pain patients.15 Therefore, it is highly prob-
able that people with COPD who experience substantial pain
will demonstrate similar consequences. To date, the severity
of pain in people with COPD and its association with physical
activity and quality of life have not been studied extensively.
The purpose of this study was to determine if pain severity
and interference with activities are more common in COPD
patients than in healthy people and if pain is related to self-
reported physical activity and health related quality of life
(HRQoL). Another aim was to determine independent
correlates of pain in COPD patients.
Methods and materials
Approval for the study was obtained from the Clinical
Research Ethics Board of the University of British Columbia.Subjects
Sedentary healthy people, and people with moderate to
severe COPD (FEV1 < 80% predicted, FEV1/FVC < 0.7),
2 over
50 years of age, matched for age and gender participated in
a cross-sectional survey study. Exclusion criteria were: (1)
comorbidities that interfered with independent ambula-
tion; (2) lack of English fluency or cognitive impairment
that interfered with the ability to provide informed consent
or to complete the questionnaires. People with COPD were
also excluded if they had an acute exacerbation within the
last three months. Sedentary healthy people were excluded
if they had self-reported respiratory conditions, such as
bronchitis, emphysema, moderate to severe asthma or if
they met exclusion criteria (1) or (2) stated above. COPD
patients were recruited from the caseload of respirologists
and pulmonary rehabilitation programs at local hospitals.
Healthy people were recruited from the posters at local
community centers and newspaper advertisements.
Outcomes and measurements
Participants were initially screened using a standardized
questionnaire via telephone. Chart reviews were performed
on all COPD participants in order to confirm the diagnosis of
COPD. After obtaining informed consent, standard survey
methods were employed by mailing a package of forms and
questionnaires to participants.16 The package included:
instructions, a form to record medications and comorbid-
ities, the Medical Outcomes Study Short Form-36 (SF-36),
the short form of the McGill Pain Questionnaire (MPQ), the
short form of the Brief Pain Inventory (BPI), the Community
Health Activities Model Program for Seniors (CHAMPS), and
the modified Tampa Scale for Kinesiophobia (TSK). One
week later, all subjects were contacted by telephone to
address any questions. Subjects were asked to return
packages in a self-addressed stamped envelope by mail.
Pain characteristics
The MPQ questions pain characteristics over the past week
and consists of: 1) 15 sensory related items; 2) 4 affective
related items; 3) the visual analog scale to provide the
intensity pain score. A fourth component, evaluates
Present Pain Intensity (PPI).17
The BPI measures the intensity of pain (sensory dimen-
sion), uses body diagrams to indicate pain location, and
evaluates interference of pain in the patient’s life
(including general activity, mood, sleep, enjoyment of life,
and relationship with others). It also asks the patient about
pain relief, pain quality, and pain medications. Because of
these different attributes, the BPI and MPQ were used to
provide a more comprehensive description of the pain
experienced by individuals.18 Both MPQ19,20 and BPI21,22
have been established as valid and reliable tools for
assessing pain severity and interference.
The TSK evaluates the pain-related fear of (re)injury
due to movement and activities. The TSK consists of 17
questions which identify fear of injury/re-injury due to
activities with item scores ranging from 1 (strongly
disagree) to 4 (strongly agree) which are tallied to
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modified version of TSK was used (without reversed key
items) as it has been found to improve the internal
consistency.23
Physical activity
The Community Health Activities Model Program for Seniors
(CHAMPS) questionnaire includes 41 questions that ask the
participants to rate the length of time spent on a variety of
activities in a typical week during the past month. It
includes physical and leisure activities that vary in intensity
including household chores and several non-physical activ-
ities (such as reading, card games, and social participa-
tion). This provides a broad selection of activities such that
respondents tend to minimize overestimation of physical
activities. The CHAMPS questionnaire provides measures for
frequencies and estimated energy expenditure for
moderate and high intensity activities.24
Health related quality of life
The SF-36 contains 36 items distributed across eight
domains (physical-functioning, role-physical, bodily pain,
general health, vitality, social-functioning, role-emotional,
and general health perception), and has two component
scales (physical and mental).25
The data related to medications and comorbidities were
obtained using self-report questionnaires. In addition,
patients’ medical charts and hospital databases were
reviewed to verify the medications and comorbidities.
Medications were coded according to the Canadian Medical
Association.26
Statistical analysis
Precise sample size calculation was not possible as similar
studies have not been performed. However, comparing
a group of healthy subjects with a patient group, we
expected to have a medium effect size (0.5). Therefore,
a sample size of 65 in each group would provide a power
for a t-test with an a2 < 0.05 to be more than 0.8.
27
However, sampling was stopped after statistically signifi-
cant differences were achieved.
Normal distribution of the data was confirmed by
inspecting the histograms and normality plots. Frequencies
were determined for the total number of pain locations,
comorbidities and medications in addition to the number of
participants that had at least one pain location, one
comorbidity or one medication. MPQ, BPI, and TSK scores
were calculated as the percentage of the maximum score
that could be obtained on each questionnaire. Two-tailed t-
tests were performed to examine for differences in pain
severity (MPQ and BPI), pain interference (BPI), physical
activity, pain-related fear of movement/re-injury (TSK),
number of pain locations, HRQoL, number of comorbidities,
and number of medications between healthy people and
those with COPD. The chi-square test was performed to
detect between group differences in the number of
subjects who reported pain for different body locations,the number of subjects who had at least one comorbidity,
and the number who reported at least one medication.
Means and standard errors are reported unless otherwise
specified. A p value <0.01 was set to indicate significant
differences.
Correlations were performed amongst pain measures in
order to determine their convergent and discriminant val-
idity. Independent correlates that might be predictive of
pain were determined by performing correlation analysis
followed by linear regression. Correlations between pain
measures (severityeby MPQ and BPI and interference by BPI
severity) and potential predictors of pain (TSK, CHAMPS,
comorbidities, medications) were examined using two-
tailed Pearson product moment correlations. Variables
that were moderately to highly correlated to pain severity
and interference scores (p < 0.01 and r > 0.40) were
entered into the linear regression model. The model was
not controlled for age and gender as the groups were
initially matched for these factors. The outcomes were
checked for multicollinearity; if two measures were highly
correlated, one was removed (e.g. medications removed
because of high correlation with comorbidities).Results
Forty-seven COPD patients and 47 healthy people
completed all questionnaires. The groups were 70  6.7
(SD) and 68.2  8.8 (SD) years, respectively. Both groups
had female:male ratios of 20:27 and the COPD group had an
FEV1 of 44.7  19.2 (SD) percent predicted. Originally 87
healthy people and 92 people with COPD were recruited for
the study; sixty-three healthy (72%) and 65 people (70%)
with COPD completed the study. To match groups for age
and gender, people younger than 55 and older than 86 were
excluded from the study, which resulted in 47 (female/
male Z 20/27) participants in each group. Considering
a medium effect size of 0.5 in order to have a power of
more than 0.8 using a t-test at a2<0.05,
27 we originally
aimed for 75 people in each group. However, we stopped
the recruitment when we reached the significance level of
(p < 0.000) for primary outcomes.
Severity of pain (measured by the MPQ and BPI), bodily
pain (lower score indicates more pain for SF-36) and pain
interference (measured by BPI) was greater in COPD
patients than in healthy people (Table 1; p < 0.000). The
number of COPD patients with moderate to very severe pain
was 7.5 and 2.2 times greater than for healthy people
evaluated by the MPQ and BPI, respectively (Fig. 1;
p < 0.002). The number of COPD patients who had
moderate to very high pain interference with activities was
5.4 fold greater than for healthy people (Fig. 1; p < 0.002).
The number of pain locations was greater in COPD patients
compared to healthy people with the most common
occurrence in the neck and trunk region (Fig. 2; p < 0.005).
COPD patients also had a greater pain-related fear of
movement/re-injury (TSK e Table 1; p < 0.001) than
healthy people.
Significant correlations amongst pain measures are
shown in Table 2. Pain severity and interference measured
by the MPQ and BPI showed strong correlations27 amongst
the three measures in each of the participant groups and in
Table 1 Measures of pain, physical activity, health related quality of life, medication and comorbidities in healthy people and
COPD patients.
Outcomes Healthy mean  SE COPD mean  SE Absolute mean difference Fold difference P value
Pain measures
Severity e MPQ 3.8  0.7 10.0  1.4 6.3 2.63 0.000
Severity e BPI 12.4  1.9 28.5  3.5 16.1 2.30 0.000
Bodily pain SF-36 76.7  3.2 49.1  4.2 27.60 0.64 0.000
Interference e BPI 9.7  1.8 35.5  4.1 25.8 3.66 0.000
Fear of movement e TSK 22.2  0.8 27.0  1.0 4.7 0.21 0.001
Number of pain locations 1.3  0.2 3.1  0.4 1.8 2.38 0.000
Physical activity e CHAMPS
All activities e EE 4184  309 1748  221 2435 0.42 0.000
Moderate EE (MET  3.0) 2560  239 710  135 1849 0.28 0.000
Number of comorbidities 1.77  0.23 3.85  0.30 2.08 2.18 0.000
Number of medications 2.21  0.34 6.64  0.54 4.43 3.00 0.000
Health related quality of life
Physical component score 52.0  1.3 35.2  1.7 16.9 0.68 0.000
Mental component score 54.7  1.30 42.0  1.8 12.8 0.78 0.000
MPQ, McGill Pain Questionnaire-short form; BPI, Brief Pain Inventory-short from; TSK, Modified Tampa Scale of Kinesiophobia; CHAMPS,
Community Health Activities Model Program for Seniors; SE: standard error of difference.
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moderate to strong correlations27 with analgesic medica-
tions and the number of pain locations in the COPD patients
and both groups. Pain-related fear of movement/re-injury
(TSK) was correlated to a lesser degree to MPQ and BPI
pain measures in the COPD patients and both groups; only
pain interference (BPI) was correlated to pain-related fear
of movement (TSK) in COPD patients.
Self-reported physical activity (CHAMPS) was lower in
COPD patients compared to healthy people (Table 1;
p < 0.000), and the total energy expenditure estimated
from CHAMPS demonstrated a moderate inverse correla-
tion27 to pain interference (BPI) (r Z 0.294, p Z 0.004)
for both groups. Physical and Mental Component Scores of
the SF-36 were lower in COPD patients than in healthy
people (Table 1; p < 0.000). Pain severity (measured by theFigure 1 Number of healthy people and COPD patients that
self-reported moderate, severe or very severe for pain severity
(McGill Pain Questionnaire [MPQ] and Brief Pain Inventory
[BPI]) and pain interference (BPI). * indicates significant
difference from healthy people at p < 0.002.MPQ and BPI) and pain interference showed moderate to
strong negative correlations27 to the Physical Component
Score of the SF-36 (0.45, 0.61, 0.70, respectively;
p Z 0.000).
Regarding the number of comorbidities and medications,
COPD patients had a greater frequency of self-reported
circulatory (47 versus 22; p Z 0.002), musculoskeletal (33
versus 14; p Z 0.005), digestive (15 versus 3; p Z 0.001),
and renal diseases (11 versus 3; p Z 0.02) compared to
healthy people. In accordance, COPD patients had a greater
numbers of respiratory (p Z 0.000), cardiovascular
(p Z 0.030), immune (0.008), and analgesic medications
(p Z 0.030) than the healthy group.
From the regression analysis, only the number of
comorbidities was a significant independent correlate of
pain severity (MPQ and BPI) in people with COPD (Fig. 3;
r Z 0.61 and 0.56, respectively; p Z 0.000).Figure 2 Number of pain locations in healthy people and
COPD patients. ** indicates significant difference at
p < 0.005.and * indicates a tendency to be different from
healthy people at p < 0.04.
Table 2 Significant correlations amongst pain measures in healthy people and COPD patients at p < 0.01. r (p value) are
shown.
FEV1 Pain
severity e MPQ
Pain
severity e BPI
TSK e pain-
related fear
of movement
Analgesic
meds
Number of pain
locations
Pain severity e MPQ
Healthy e e e 0.39 (0.007)
COPD e e 0.38 (0.009) 0.68 (0.000)
Both groups e 0.362 (0.000) 0.42 (0.000) 0.67 (0.000)
Pain severity e BPI
Healthy e 0.77 (0.000) e 0.36 (0.013) 0.44 (0.002)
COPD 0.46 (0.003) 0.82 (0.000) e 0.54 (0.000) 0.683 (0.000)
Both groups e 0.76 (0.000) 0.36
(0.000)
0.54 (0.000) 0.681 (0.000)
Pain interference e BPI
Healthy e 0.72 (0.000) 0.82, (0.000) e 0.38 (0.008) 0.46 (0.001)
COPD 0.56 (0.000) 0.66 (0.000) 0.74, (0.000) 0.49 (0.001) 0.36 (0.012) 0.58 (0.000)
Both groups e 0.73 (0.000) 0.79, (0.000) 0.52 (0.000) 0.42 (0.000) 0.63 (0.000)
MPQ, McGill Pain Questionnaire-short form; BPI, Brief Pain Inventory-short from; TSK, Modified Tampa Scale of Kinesiophobia; FEV1,
forced expiratory volume in 1 s.
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Our study demonstrated that people with COPD report
almost 2.5 times greater pain compared to healthy adults.
In addition, pain interferes with daily activities 3.7 times
more often in people with COPD than in healthy people.
Furthermore, not only is pain more severe, but it is also
more common in people with COPD. Moderate to severe
pain was self-reported 2.2 and 7.5 times more often in
COPD patients than matched healthy people as measured
by the BPI and MPQ, respectively. Moderate to severe pain
affected half of our COPD sample of participants, a rate
which falls between the 25e70% found in end-of-life COPD
patients reporting pain5 and a rate much higher than theFigure 3 Scatter plots depicting relationship between McGill an
comorbidities. Adjusted R2 and p values are shown for both groups20% who reported more than low intensity chronic pain in
a large survey (n Z 3605) of general practice patients.28
Greater pain in people with COPD might be due to more
prolonged induction of painful stimuli or possibly to lower
thresholds for pain compared to healthy people. Possible
etiologies could be systemic inflammation, central adap-
tations related to pain and dyspnea, and musculoskeletal
disorders including mechanical limitation of chest wall
movement due to hyperinflation.
Systemic inflammation in COPD may provide one expla-
nation for increased pain severity in these patients. The
macrophage and neutrophilic response central to the
etiology of the lung disease29 results in the release of large
amounts of proinflammatory cytokines that perpetuated brief pain inventory pain severity scores and the number of
. Data for the COPD group is provided in the text.
Pain in COPD 1003a local inflammatory response and can also impact distant
tissues via the circulation.30,31 TNF-a has been shown to
increase mechanical allodynia and thermal hyperalgesia32
and decrease the mechanical activation threshold in C
fibers.33 It is involved in the generation and the mainte-
nance of neuropathic pain.34 Moreover, IL-1b is considered
to be a key cytokine associated with increased pain and
hyperalgesia, especially in neuropathies and inflammatory
diseases.9,35 Marked increase in cytokine IL-6 is associated
with increased pain and hyperalgesia.36 Thus, proin-
flammatory cytokines can induce or increase inflammatory
pain. Given that COPD is associated with marked and pro-
longed systemic elevation of inflammatory cytokines due to
lung pathology, it is tenable that this systemic inflammation
may contribute to the generation of pain or lower the
threshold to painful stimuli.
COPD patients may have an altered sensation to pain due
to protracted central processing of dyspnea and pain. In
addition to their common unpleasant, alarming character,
recurrence of chronic experiences of dyspnea or pain are
prominent and threatening symptoms in several pulmonary
diseases such as asthma37 and COPD.2 Both pain and dysp-
nea have been mapped to activation of common brain areas
including the anterior/mid insula, dorsal anterior cingulate
cortex, sensorimotor and somatosensory cortex II, supple-
mentary motor area, amygdale and medial thalamus.37,38
Due to similar sensory and affective-related brain
networks, the protracted experience of dyspnea in COPD
patients and associated prolonged activation of brain
centers may induce permanent changes in the perception
of pain, especially after sensitization. Whether or not the
reduced sensitivity to discriminate between different
noxious and non-noxious stimuli, such as pain and dyspnea
at cortical level, is affected by sensitization and is impaired
in people with COPD requires further investigation.
The pain severity and interference scores are somewhat
similar to those previously reported. The pain severity
score of BPI in our study is lower to that of Borge et al.7
(28.5/100 versus 3.7/10), whereas the pain interference
scores in our study are similar (35.5/100 versus 3.9/10).
These results are similar to those of previous studies, which
reported marked pain in COPD patients.5e7,39 Regarding SF-
36 data, Hajiro et al.8 found higher scores in the pain
domain (indicated better HQoL) compared to our pain
domain scores of the SF-36. However, these authors also
suggested that this domain had a small number of items,
which may “bring less discriminatory power to the SF-36
when evaluating the HRQOL of patients with stable COPD.”
Of interest, pain in the neck and trunk was more
common than in other body locations, which is consistent
with previous studies.7,39 This finding might be attributable
in part, to the location of the primary and accessory
muscles of respiration. For example, the diaphragm and
intercostal muscles might be overused during the abnormal
breathing pattern in COPD7,39 accentuated by their
mechanical disadvantage due to hyperexpansion of the
chest wall. Chest wall hyperinflation in COPD consequent to
alveolar destruction and airway inflammation results in the
resting position of the chest wall being shifted to the left on
the pressureevolume curve causing higher volumes with
a decreased available range of motion during ventilation,
i.e. decreased thoracic excursion. This hyperinflation isaccentuated by exertion even during such functional tests
as the 6 min walk test.40 The limited range of motion due to
hyperinflation may result in reactive muscle spasm similar
to what occurs in other conditions with limited range of
motion of joints and reduced operating lengths of muscle,
such as osteoarthritis.12 In addition to joint pain and muscle
spasm, the mechanical disadvantage of the inspiratory
muscles in the hyperinflated state, compounded by
increased levels of tidal ventilation, may make these
muscles more prone to overuse injury and subsequent
delayed onset muscle soreness (DOMS) as evidenced by
microscopic muscle injury in COPD patients.41 DOMS of the
inspiratory muscles has been reported in healthy people.42
In summary, the mechanical abnormalities of the thorax
due to hyperinflation and increased levels of ventilation
may contribute to joint pain, muscle spasm and delayed
onset muscle soreness in people with COPD.
Our data indicates that the frequency and number of
COPD patients with self-reported musculoskeletal disease is
about double that found in healthy adults; this difference
likely contributes to the two- to three-fold greater number
of pain locations in the upper and lower extremities
compared to healthy people. We did not explore the types
of musculoskeletal comorbidities that might contribute to
pain in our study samples. However, osteoporosis is
commonly reported (60e70%) in COPD14 and age-related
prevalence of osteoarthritis ranges from 14 to 58%13 in
the 50e86 year age-range of our study participants. Along
with joint specific pathologies, systemic influences of
inflammatory cytokines and central processing of altered
sensations may also increase pain experienced in the
extremities by COPD patients compared to healthy people.
The number of comorbidities was found to be an inde-
pendent correlate of pain severity in people with COPD, as
measured by MPQ and BPI. This result is not surprising given
that many comorbidities manifest with pain symptoms.43
During a week-long general practice survey, 22% of
approximately 3,000 patients presented with pain as
a primary complaint with the most common underlying
cause being musculoskeletal (50%) followed by visceral
including cardiovascular (20%), infectious (15%) and head-
aches (8%). From a mail survey of general practice patients,
the subsample of those who were 55 yrs or older, attributed
pain most often to musculoskeletal causes (w40%) and
angina (6.3%) [55e64 yr] to 11.1% [75 yr].28 In comparison,
just over 50% of COPD patients complained of pain and self-
reported cardiovascular conditions (67%) and musculoskel-
etal conditions (51%), which may be primary sources of pain
in our survey sample. Further investigation is required to
determine the contributing factors to the etiology of pain in
COPD patients.
The significance of pain in people with COPD was
reflected in greater pain-related interference in activities
(BPI) that may partly explain the lower Physical Component
Scores in HRQoL (SF-36) and the lower physical activity
scores (CHAMPS questionnaire) in people with COPD
compared to healthy adults. Patients with COPD also
experience greater pain-related fear as indicated by the
scores on the modified TSK, a finding which is similar to
chronic pain patients compared to healthy people.43 Pain
sufferers can worry about how increasing pain may lead to
progressive disability and this can be heightened if they
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and health care providers. Fear and anxiety are also asso-
ciated with pain-exacerbating activities, such as avoidance
of physical activity, that can further reduce muscle flexi-
bility, strength, and endurance leading to a downward
spiral of increased disability.43 Indeed, fear of movement
and injury are better predictors of functional limitations
than biomedical parameters or even pain severity and
duration.44 Treating symptoms of fear and anxiety, and also
establishing pain coping strategies is essential for opti-
mizing pain management.
To date, pain does not appear to be strongly associated
with the severity of airflow limitation. We did not find
a significant relationship between FEV1 and pain severity
score of MPQ, similar findings to those of previous studies
that examined the severity of pain measures with spirom-
etry.7,45,46 That being said, these results do contrast the
moderate correlation that we found between BPI severity
and interference scores and FEV1. One plausible explana-
tion might be that in our sample, people with minor disease
severity may be more active and expose themselves to
more extraneous activities that can induce pain. Given
these disparate findings, further research is required to
clarify the relationship between pain and disease severity.
Limitations
The primary limitation of this study is the use of self-report
questionnaires. However, the participant’s perception is
essential to evaluate subjective sensations such as pain.
Other constructs evaluated, such as activities, comorbid-
ities and medications can be underestimated or over-
estimated using this method of inquiry.16 In addition, the
study sample was a convenience sample and relatively
small; thus, it is difficult to determine if the two sample
groups were affected unequally by self-selection and
recruitment, although given the high response rate of
participants in both groups, these effects might be
minimal. The study sample also came from a small
geographical location. The experience and underlying
causes of pain may vary in different cultures because of
associated variations in the prevalence of disorders causing
pain and pain perceptions. Furthermore, this study did not
examine the effects of dyspnea, a major symptom of
people with COPD. Future studies need to investigate the
relationship between dyspnea and pain (commonalities and
differences), as the perception of dyspnea shares many
characteristics with the perception of pain, and both
sensations might be linked to affective states.
Conclusion
Compared to their healthy counterparts, pain is more
common and of a greater magnitude in people with COPD.
The relationship between pain interference and daily
physical activities requires further exploration to deter-
mine whether or not pain is a major contributor to
decreased physical activity and HRQoL in COPD patients.
The assessment and treatment of pain is often overlooked
in the plan of care for COPD patients. A greater apprecia-
tion of factors involved in pain perception will be beneficialfor designing COPD-specific pain management programs
aimed at improving physical, psychological, and social well-
being in people with COPD.Conflict of interest
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